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WS2.5 Airway epithelial regeneration is abnormal in CF in absence of
endogenous infection and inﬂammation
D. Adam1, J. Roux1, S. Linge´e1, B. Nawrocki-Raby1, P. Birembaut1, C. Coraux1.
1INSERM UMRS 903, Reims, France
In CF, the airway epithelium is frequently remodeled and has to rapidly regenerate
its structure. Whether these alterations are related to infection and/or inﬂammation
or to a dysregulated regeneration process remains to be elucidated. Previously, we
showed in an aseptic xenograft model that CF epithelial regeneration is delayed
and reconstitute a remodeled epithelium. The aim of the present study was to
determine if CF airway epithelial regeneration is abnormal in absence of endogenous
inﬂammation.
CF and non-CF epithelial cells collected from aseptic nasal polyps were cultured at
the air-liquid interface. Histology and cell proliferation were examined on culture
sections after histological or immunological staining. Epithelial functionality was
assessed in terms of electrical properties and bactericidal activity of epithelial
secretions.
In absence of endogenous inﬂammation, the CF epithelial regeneration is delayed.
The regenerated epithelium is remodeled, exhibits basal cell hyperplasia and is
signiﬁcantly thicker compared to non-CF. However, a delay in cell proliferation,
rather than hyperproliferation, is observed. Finally, the CF regenerated epithelium
is not functional.
We show here that in absence of exogenous infection and inﬂammation, the CF
regenerated epithelium is a remodeled. This strongly suggests the involvement of
the basic CFTR default in this phenomenon. To verify this hypothesis, we will
examine the regeneration process of cells after treatment with CFTR correctors or
CFTR-encoding lentiviral vectors to correct CF cells, as well as CFTR siRNAs to
silence CFTR in non-CF cells.
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The main cause of morbidity and mortality in cystic ﬁbrosis (CF) is due to lung
damage resulting from chronic bacterial infection and inﬂammation and a reduced
ability of the epithelium to repair. Reduced levels of the anti-inﬂammatory mediator
LipoxinA4 (LXA4) have been reported in the bronchoalveolar lavages of patients
with CF. We investigated the LXA4 ability to trigger epithelial repair in CF airways.
Spontaneous epithelial repair was signiﬁcantly slower in CF epithelial cultures
(Cuﬁ-1 homozygous F508del) compared to controls (Nuli-1). LXA4 stimulated
a dose-dependent increase in cell proliferation (MTT) and repair (Scratch Assay) in
NuLi-1 cells but also to a greater extent in CuFi-1 cells. The levels of the lipoxin
receptor, FPR2 (FACS) were found to be signiﬁcantly lower in CF cells. LXA4
induced cell proliferation was inhibited by the FPR2 receptor antagonist, Boc-2,
the MAP kinase (ERK1/2) inhibitor, PD98059, and the KATP channel inhibitor,
glybenclamide. The KATP channel opener, pinacidil, alone signiﬁcantly stimulated
cell proliferation and showed a slight additive effect in combination with LXA4.
Although LXA4 did not affect K
+ channel mRNA expression, LXA4 increased the
Barium (K+ channel inhibitor)-sensitive whole-cell currents.
Taken together our results indicated that LXA4 triggers epithelial repair and
proliferation of CF cells, through stimulation of the FPR2 receptor followed by
ERK and KATP potassium channel activation. These results suggest that the decrease
of the endogenous LXA4 reported in CF contributes to the reduced ability of CF
airway epithelium to repair and highlights the use of exogenous LXA4 as a potential
therapeutic in CF.
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Cystic Fibrosis (CF) males survive 9 years longer than females (“CF gender gap”)
and lung exacerbations in CF females vary during the estrous cycle. 17b-estradiol
(E2) has been reported to reduce airway surface liquid (ASL) height in female
CF bronchial epithelium. Here we investigated the effect of estrogen on ASL
height and ion transport in normal (NuLi-1) and CF (CuFi-1) bronchial epithelium
monolayers. Confocal ﬂuorescence microscopy experiments revealed that ASL
height was signiﬁcantly higher in the non-CF cell line compared to CF cells.
E2 (0.1 to 10 nM) reduced ASL height in both non-CF and CF cell lines after
30 min treatment. Treatment with the Cl− transport inhibitor bumetanide (10mM)
decreased ASL height signiﬁcantly in both cell lines. However, E2 had no additive
effect on ASL height in the presence of this ion transporter inhibitor. E2 decreased
bumetanide-sensitive Cl∗minus; current in normal cells and produced an increase in
amiloride (10mM) sensitive current in CF cells. Treatment with the nuclear-impeded
Estrogen Dendrimer Conjugate (0.1−1 nM E2 equivalent concentration) produced a
reduction in ASL height in CF and non-CF whereas the empty dendrimer did not
show any effect. These results demonstrate that E2 dehydrates CF and normal
ASL via a membrane-initiated rather than the classical nuclear receptor signal
transduction pathway. The ion transporter inhibitor data indicate that E2 acts on
ASL by inhibiting Cl− secretion in non-CF cells and increasing Na+ absorption in
CF cells.
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Recent studies have shown that allergic airway disease induces enhanced epithelial
Cl− secretion in mouse airways. However, the molecular identity of the underlying
Cl− conductance remains unknown. Slc26a9 is a recently identiﬁed Cl− channel.
To determine its role in allergic airway disease, we induced Th2-mediated airway
inﬂammation by intratracheal instillation of IL-13 in mice and compared effects
on ion transport, morphology and mucus content in airways from wild-type and
Slc26a9-deﬁcient mice. We show that IL-13 enhanced constitutive Cl− secretion
in airways from wild-type, but not Slc26a9-deﬁcient mice. While IL-13 induced
mucus overproduction was similar in both genotypes, lack of Slc26a9-mediated
Cl− secretion caused signiﬁcant airway mucus obstruction in IL-13 treated Slc26a9-
deﬁcient mice that was not seen in wild-type controls. Our data demonstrate that the
Slc26a9 Cl− channel is activated in airway inﬂammation and suggest that Slc26a9-
mediated Cl− secretion is essential to maintain airway surface liquid homeostasis
and mucus clearance thus preventing airway obstruction in allergic airway disease.
These results indicate that Slc26a9 may serve as a novel therapeutic target in airway
diseases associated with mucus plugging, such as CF.
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